Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1988 1
1991 2
1992 1
1993 1
1994 3
2003 2
2004 1
2006 1
2007 1
2008 1
2010 2
2011 1
2012 2
2013 4
2014 4
2015 8
2016 8
2017 4
2018 3
2019 3
2020 2
2021 2
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Outcomes after Endovascular Treatment Failure in Patients with Femoropopliteal Occlusive Disease.
Hernández Mateo MM, Martínez López I, Revuelta Suero S, Marqués de Marino P, Cernuda Artero I, Cabrero Fernández M, Serrano Hernando FJ. Hernández Mateo MM, et al. Ann Vasc Surg. 2016 Jan;30:299-304. doi: 10.1016/j.avsg.2015.07.039. Epub 2015 Nov 2. Ann Vasc Surg. 2016. PMID: 26541966
BACKGROUND: To analyze the clinical impact derived from endovascular treatment failure on patients with femoropopliteal occlusive disease (FPOD) regarding their preoperative clinical stage. ...No predictors were obtained regarding clinical worsening an …
BACKGROUND: To analyze the clinical impact derived from endovascular treatment failure on patients with femoropopliteal occlusive …
Management of isolated femoropopliteal in-stent restenosis.
Qato K, Conway AM, Mondry L, Giangola G, Carroccio A. Qato K, et al. J Vasc Surg. 2018 Sep;68(3):807-810. doi: 10.1016/j.jvs.2018.01.030. J Vasc Surg. 2018. PMID: 30144908 Free article.
We evaluated the midterm outcomes of patients with asymptomatic isolated femoropopliteal ISR who were observed under a surveillance program. METHODS: Patients treated with isolated femoropopliteal stents from January 2009 to December 2013 were retrospectively investigated …
We evaluated the midterm outcomes of patients with asymptomatic isolated femoropopliteal ISR who were observed under a surveillance p …
Mortality in randomised controlled trials using paclitaxel-coated devices for femoropopliteal interventional procedures: an updated patient-level meta-analysis.
Parikh SA, Schneider PA, Mullin CM, Rogers T, Gray WA. Parikh SA, et al. Lancet. 2023 Nov 18;402(10415):1848-1856. doi: 10.1016/S0140-6736(23)02189-X. Epub 2023 Oct 24. Lancet. 2023. PMID: 37890499
BACKGROUND: Numerous randomised clinical trials and real-world studies have supported the safety of paclitaxel-coated devices for the treatment of femoropopliteal occlusive disease. However, a 2018 summary-level meta-analysis suggested an increased mortality …
BACKGROUND: Numerous randomised clinical trials and real-world studies have supported the safety of paclitaxel-coated devices for the treatm …
The impact of inflow treatment for claudicants with both aortoiliac and femoropopliteal occlusive disease.
Maekawa T, Komori K, Kodama A, Banno H, Narita H, Sugimoto M. Maekawa T, et al. Surg Today. 2017 Mar;47(3):293-300. doi: 10.1007/s00595-016-1399-0. Epub 2016 Sep 1. Surg Today. 2017. PMID: 27586013
RESULT: After inflow revascularization, almost complete relief from intermittent claudication was seen in 79 % of the limbs, while 21 % of the limbs continued to suffer from disabling claudication. A multivariate analysis showed that a run-off score of 7 was an independent …
RESULT: After inflow revascularization, almost complete relief from intermittent claudication was seen in 79 % of the limbs, while 21 % of t …
Risk factors for clinical failure after stent graft treatment for femoropopliteal occlusive disease.
Johnston PC, Vartanian SM, Runge SJ, Hiramoto JS, Eichler CM, Owens CD, Schneider DB, Conte MS. Johnston PC, et al. J Vasc Surg. 2012 Oct;56(4):998-1006, 1007.e1; discussion 1006-7. doi: 10.1016/j.jvs.2012.03.010. Epub 2012 May 25. J Vasc Surg. 2012. PMID: 22633429 Free article.
OBJECTIVE: Optimal selection of a revascularization strategy in femoropopliteal occlusive disease (FPOD) remains controversial. Among endovascular treatment options for FPOD, covered stent placement has become increasingly used. ...Lesions treated included 45 …
OBJECTIVE: Optimal selection of a revascularization strategy in femoropopliteal occlusive disease (FPOD) remains contro …
Long-term clinical outcomes after self-expandable bare nitinol stent implantation for femoropopliteal occlusive disease in hemodialysis patients.
Ito R, Ishii H, Oshima S, Nakayama T, Takahashi H, Sakakibara T, Kakuno M, Murohara T. Ito R, et al. Catheter Cardiovasc Interv. 2021 Feb 1;97(2):318-324. doi: 10.1002/ccd.29372. Epub 2020 Nov 12. Catheter Cardiovasc Interv. 2021. PMID: 33179857
Over the following 5 years, the incidence of target lesion revascularization (TLR), major amputation and mortality was investigated. We also performed propensity-score matching analysis. RESULTS: The 5-year TLR rate (45.2 vs. 32.5%, p = .013) and mortality rate (39.3 vs. 1 …
Over the following 5 years, the incidence of target lesion revascularization (TLR), major amputation and mortality was investigated. We also …
Determination of Risk Factors and Establishment of a Prediction Model for Immediate Technical Failure during Endovascular Treatment of Femoropopliteal Occlusive Disease.
Qiu YH, Yu GF, Zhou HH, Xia HW, Chen L, Chen HT, Jiao YY, Wu ZH, Zheng XT. Qiu YH, et al. Ann Vasc Surg. 2018 Apr;48:35-44. doi: 10.1016/j.avsg.2017.09.024. Epub 2017 Dec 5. Ann Vasc Surg. 2018. PMID: 29217435
Therefore, this study aims to reveal risk factors and establish a prediction model of ITF of EVT in femoropopliteal occlusive disease (FPOD) patients based on preoperative clinical date that may be helpful to the clinical procedures. ...We determined t …
Therefore, this study aims to reveal risk factors and establish a prediction model of ITF of EVT in femoropopliteal occlusi …
Clinical consequence of bare metal stent and stent graft failure in femoropopliteal occlusive disease.
Vartanian SM, Johnston PC, Walker JP, Runge SJ, Eichler CM, Reilly LM, Hiramoto JS, Conte MS. Vartanian SM, et al. J Vasc Surg. 2013 Dec;58(6):1525-31. doi: 10.1016/j.jvs.2013.05.094. Epub 2013 Jul 30. J Vasc Surg. 2013. PMID: 23911250 Free article.
OBJECTIVE: The optimal role for bare metal stents (BMS) or stent grafts (SG) in femoropopliteal occlusive disease (FPOD) is as of yet undefined. Understanding the clinical consequences of failure can help guide initial treatment decisions. ...Although the ove …
OBJECTIVE: The optimal role for bare metal stents (BMS) or stent grafts (SG) in femoropopliteal occlusive disease (FPOD …
Safety and efficacy of antiplatelet/anticoagulation regimens after Viabahn stent graft treatment for femoropopliteal occlusive disease.
Ullery BW, Tran K, Itoga N, Casey K, Dalman RL, Lee JT. Ullery BW, et al. J Vasc Surg. 2015 Jun;61(6):1479-88. doi: 10.1016/j.jvs.2014.12.062. Epub 2015 Feb 19. J Vasc Surg. 2015. PMID: 25704407 Free article.
Gore & Associates, Flagstaff, Ariz) for the treatment of femoropopliteal occlusive disease. METHODS: Clinical, angiographic, and procedural data for patients undergoing endovascular treatment of femoropopliteal occlusive disease using …
Gore & Associates, Flagstaff, Ariz) for the treatment of femoropopliteal occlusive disease. METHODS: Clinical, angi …
50 results